Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(Nivolumab + relatlimab) by Bristol-Myers Squibb for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase II for Adenocarcinoma Of The Gastroesophageal...
(Nivolumab + relatlimab) by Bristol-Myers Squibb for Gastric Cancer: Likelihood of Approval
(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase II for Gastric Cancer. According to...
LM-302 by Bristol-Myers Squibb for Ovarian Cancer: Likelihood of Approval
LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Relatlimab by Bristol-Myers Squibb for Melanoma: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Nivolumab by Bristol-Myers Squibb for Pleomorphic Liposarcoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pleomorphic Liposarcoma. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Angiosarcoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II...
Nivolumab by Bristol-Myers Squibb for Chondrosarcoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II...
Nivolumab by Bristol-Myers Squibb for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pediatric Diffuse Intrinsic Pontine Glioma. According...
Nivolumab by Bristol-Myers Squibb for High-Grade Glioma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase...
Relatlimab by Bristol-Myers Squibb for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
Nivolumab by Bristol-Myers Squibb for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for Merkel Cell Carcinoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According...
Nivolumab by Bristol-Myers Squibb for Prostate Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma)....
Nivolumab by Bristol-Myers Squibb for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Nivolumab by Bristol-Myers Squibb for Skin Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Skin Cancer. According to GlobalData, Phase...
BMS-986178 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-986178 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's BMS-986012?
BMS-986012 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Small-Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Milvexian?
Milvexian is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Atrial Flutter. According to...